nach oben

Erschienen in:

01.07.2011 | Original Communication

Vascular risk factors are associated with faster decline of Alzheimer disease: a longitudinal SPECT study

verfasst von: Kazumasa Kume, Haruo Hanyu, Tomohiko Sato, Kentaro Hirao, Soichiro Shimizu, Hidekazu Kanetaka, Hiofumi Sakurai, Toshihiko Iwamoto

Erschienen in: Journal of Neurology | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

We investigated the effects of cardiovascular risk factors, such as hypertension, diabetes mellitus, and hypercholesterolemia, on longitudinal regional cerebral blood flow (rCBF) changes in Alzheimer’s disease (AD). We followed 68 outpatients with probable AD for an average of 40 months. They were divided into three groups based on no (n = 24), single (n = 27), and multiple (n = 17) vascular risk factors. We assessed longitudinal changes on the Mini-Mental State Examination, Functional Assessment Staging scores, and in rCBF deficits using repeated single photon emission computed tomography (SPECT) using N-isopropyl-p-[¹²³I] iodoamphetamine. During follow-up, the multiple vascular risk factor group showed faster cognitive and functional decline than the no and single vascular risk factor groups. When compared with the initial SPECT, the follow-up SPECT showed a significant rCBF reduction in widespread regions, including the parietotemporal, frontal, and limbic lobes, in the multiple and single vascular risk factor groups, while there was rCBF reduction in small scattered regions of the temporoparietal lobe in the no vascular risk factor group. Multiple vascular risk factors are associated with a greater rate of decline in cognition, function, and rCBF in patients with AD. Our results highlight the contribution of vascular risk factors on the progression of AD.

Beeri MS, Schmeidler J, Silverman JM et al (2008) Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 71:750–757PubMedCrossRef

Boksay I, Reisberg B, Torossian C et al (2005) Alzheimer’s disease and medical disease conditions: a prospective cohort study. J Am Geriatr Soc 53:2235–2236PubMedCrossRef

Dougall NJ, Bruggink S, Ebmeier KP (2004) Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 12:554–570PubMed

Evans RM, Hui S, Perkins A et al (2004) Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 62:1869–1871PubMed

Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef

Forette F, Seux ML, Staessen JA et al (2002) Systolic hypertension in Europe investigators. The prevention of dementia with antihypertensive treatment. New evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med 162:2046–2052PubMedCrossRef

Growdon JH, Locascio JJ, Corkin S et al (1996) Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer’s disease. Neurology 47:444–448PubMed

Han L, Cole M, Bellevance F et al (2000) Tracking cognitive decline in Alzheimer’s disease using the mini-mental state examination: a meta-analysis. Int Psychogeriatr 12:231–247PubMedCrossRef

Haxby JV, Raffaele K, Gillette J et al (1992) Individual trajectories of cognitive decline in patients with dementia of the Alzheimer type. J Clin Exp Neuropsychol 14:575–592PubMedCrossRef

10.

Helzner EP, Luchsinger JA, Scarmeas N et al (2009) Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66:343–348PubMedCrossRef

11.

Highes CP, Berg L, Danzieger WL et al (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572CrossRef

12.

Ishi K, Willoch F, Minoshima S et al (2001) Statistical brain mapping of 18F-FDG PET in Alzheimer’s disease: validation of anatomic standardization for atrophied brains. J Nucl Med 42:548–557

13.

Kivipelto M, Helkala EL, Laakso MP et al (2002) Apolipoprotein E epsilon 4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137:149–155PubMed

14.

Kleiman T, Zdanys K, Black B et al (2006) Apolipoprotein E epsilon 4 allele is unrelated to cognitive or functional decline in Alzheimer’s disease: retrospective and prospective analysis. Dement Geriatr Cogn Disord 22:73–82PubMedCrossRef

15.

Launer LJ, Ross GW, Petrovitch H et al (2000) Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 21:49–55PubMedCrossRef

16.

Li G, Larson EB, Sonnen JA et al (2007) Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 69:878–885PubMedCrossRef

17.

McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944PubMed

18.

Mielke MM, Rosenberg PB, Tschanz J et al (2007) Vascular factors predict rate of progression in Alzheimer disease. Neurology 69:1850–1858PubMedCrossRef

19.

Minoshima S, Koeppe RA, Frey KA et al (1994) Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 35:1528–1537PubMed

20.

Minoshima S, Frey KA, Koeppe RA et al (1995) A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 36:1238–1248PubMed

21.

Mizumura S, Kumita S, Cho K et al (2003) Development of quantitative analysis method for stereotactic brain image: assessment of reduced accumulation in extent and severity using anatomical segmentation. Ann Nucl Med 17:289–295PubMedCrossRef

22.

Murphy GM Jr, Taylor J, Kraemer HC et al (1997) No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer’s disease. Am J Psychiatry 154:603–608PubMed

23.

Musicco M, Palmer K, Salamone G et al (2009) Predictors of progression of cognitive decline in Alzheimer’s disease: the role of vascular and sociodemographic factors. J Neurol 256:1288–1295PubMedCrossRef

24.

Notkola IL, Sulkava R, Pekkanen J et al (1998) Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology 17:14–20PubMedCrossRef

25.

Ohrui T, Tomita N, Sato-Nakagawa T et al (2004) Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 63:1324–1325PubMed

26.

Ott A, Stolk RP, van Harskamp F et al (1999) Diabetes mellitus and the risk of dementia: the rotterdam study. Neurology 53:1937–1942PubMed

27.

Regan C, Katona C, Walker Z et al (2006) Relationship of vascular risk to the progression of Alzheimer disease. Neurology 67:1357–1362PubMedCrossRef

28.

Reisberg B, Ferris SH, Anand R et al (1984) Functional staging of dementia of the Alzheimer’s type. Ann NY Scad Sci 485:481–483CrossRef

29.

Risner ME, Saunders AM, Altman JF et al (2006) Rosiglitazone in Alzheimer’s Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenom J 6:246–254

30.

Roselli F, Tartaglione B, Federico F et al (2009) Rate of MMSE score change in Alzheimer’s disease: influence of education and vascular risk factors. Clin Neurol Neurosurg 111:327–330PubMedCrossRef

31.

Sanz C, Andrieu S, Sinclair A et al (2009) Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology 73:1359–1366PubMedCrossRef

32.

Skoog I, Lernfelt B, Landahl S et al (1996) A 15-year longitudinal study of blood pressure and dementia. Lancet 347:1141–1145PubMedCrossRef

33.

Skoog I, Lithell H, Hansson L et al (2005) Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: study on cognition and prognosis in the elderly (SCOPE). Am J Hypertens 18:1052–1059PubMedCrossRef

34.

Talairach J, Tournoux P (1998) Co-planar stereotactic atlas of the human brain. New York, Thieme

35.

The Japan Atherosclerotic Society (2007) Guidelines for prevention of atherosclerotic cardiovascular diseases. Kyowakikaku, Tokyo

36.

The Japan Diabetic Society (2010) Treatment Guide for Diabetes. Bunkodo, Tokyo

37.

The Japanese Society of Hypertension (2009) Guidelines for the management of hypertension. Life Science, Tokyo

38.

van Kan GA, Rolland Y, Nourhashemi F et al (2009) Cardiovascular disease risk factors and progression of Alzheimer’s disease. Dement Geriatr Cogn Disord 27:240–246CrossRef

39.

Yoshitake T, Kiyohara Y, Kato I et al (1995) Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama study. Neurology 45:1161–1168PubMed

Titel: Vascular risk factors are associated with faster decline of Alzheimer disease: a longitudinal SPECT study
verfasst von: Kazumasa Kume
Haruo Hanyu
Tomohiko Sato
Kentaro Hirao
Soichiro Shimizu
Hidekazu Kanetaka
Hiofumi Sakurai
Toshihiko Iwamoto
Publikationsdatum: 01.07.2011
Verlag: Springer-Verlag
Erschienen in: Journal of Neurology / Ausgabe 7/2011
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-011-5927-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2011

Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus

Mononeuropathy multiplex associated with acute parvovirus B19 infection: characteristics, treatment and outcome

GAD-ab-associated movement disorder in a male patient with breast cancer

Lamotrigine therapy for paroxysmal dysarthria caused by multiple sclerosis: a case report

Psychosocial aspects in myasthenic patients treated by plasmapheresis